Today's Date: December 1, 2023
Texas Couple Recognized with St. Jude Hero Among Us Award   •   Canadian Kids Invited to Design the Dream Car of the Future   •   MeatEater Hires Andrew Barge as Chief Content Officer   •   11 Winners Recognised at Zayed Sustainability Prize Awards Ceremony held during COP28 UAE   •   Eion Appoints Anastasia Pavlovic as Chief Executive Officer   •   Two PRA Group Leaders Win Stevie® Awards in 2023 Stevie Awards for Women in Business   •   Electra Announces Proposed Amendments to Outstanding Warrants   •   Statement on behalf of the Council of Chief Medical Officers of Health   •   Vertical Receives Continued Listing Standard Notice from NYSE   •   Sarah Jakes Roberts' Celebrated Woman Evolve Returns to Globe Life Field for Annual Women's Conference   •   Approved Oil Company Secures Exclusive Multi-Year Deal to Power All NYC Agencies with Renewable Diesel, Boosting Green Initiativ   •   Stretch Recovery Lounge Expands: Grand Opening of 6th Location – Upper East Side, New York City   •   CF Industries Holdings, Inc. to Participate in Upcoming Investor Conferences   •   ComEd Celebrates First Graduates of Technical Focused Career Training Program   •   Female Student-Athletes File Title IX Sex Discrimination Class Action Against University of Oregon   •   The Children's Home of Wyoming Conference Provides Notice Following Data Security Incident   •   NORWEGIAN CRUISE LINE'S ALL-NEW NORWEGIAN VIVA COMPLETES HER EXCLUSIVE CHRISTENING VOYAGE FOLLOWING A STAR-STUDDED EVENT IN MIAM   •   Empire BlueCross BlueShield Foundation Invests $300,000 in Housing Works’ Digital Food Market Expansion   •   State Grid Corporation of China Attended COP28 with Report on Promoting the Action for Green-oriented Transition of Energy   •   TRANSLATE HATE: HOW TO RECOGNIZE ANTISEMITIC LANGUAGE
Bookmark and Share

IQVIA Appoints Richard Staub III President of Research & Development Solutions

RESEARCH TRIANGLE PARK, N.C. , September 26 /Businesswire/ - IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit.

Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consecutive years of record-breaking backlog, posted industry leading book to bill ratios and significantly increased R&DS revenues. During his tenure Richard oversaw the rapid expansion of IQVIA’s clinical research capabilities and, critically, he successfully led this business unit through the unprecedented challenges of the COVID-19 global pandemic.

In his role as senior advisor to the Chairman and CEO of IQVIA, Richard worked closely with the R&DS team and was instrumental in R&DS’ continued success. He had responsibility for key customer relationships, provided leadership on critical business issues and continued to guide the overall strategic direction of the business.

Costa Panagos will be retiring from the organization after a 24-year career at IQVIA, where he held several positions including most recently the R&DS business unit leadership role since 2022. IQVIA would like to thank Costa for the contributions he has made to the R&DS organization over this period.

To learn more about IQVIA, visit for more information.


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit

STORY TAGS: Personnel, United States, North America, Technology, Biotechnology, Health, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, Infectious Diseases, Data Analytics, Science, COVID-19, Data Management, Clinical Trials, North Carolina,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News